Zobrazeno 1 - 10
of 264
pro vyhledávání: '"Lia, Gore"'
Autor:
Elias J. Jabbour, Hagop M. Kantarjian, Nicola Goekbuget, Bijal D. Shah, Sabina Chiaretti, Jae H. Park, Anita W. Rijneveld, Lia Gore, Shaun Fleming, Aaron C. Logan, Josep M. Ribera, Tobias F. Menne, Khalid Mezzi, Faraz Zaman, Kelly Velasco, Nicolas Boissel
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-16 (2024)
Abstract This narrative review seeks to summarize chemotherapeutic regimens commonly used for patients with newly diagnosed Philadelphia (Ph) chromosome–negative B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in the frontline setting and t
Externí odkaz:
https://doaj.org/article/43030acbfb3043f888db2a0e7df286c9
Autor:
Erin M. Guest, John A. Kairalla, Meenakshi Devidas, Emily Hibbitts, Andrew J. Carroll, Nyla A. Heerema, Holly R. Kubaney, Margaret A. August, Sidharth Ramesh, Byunggil Yoo, Midhat S. Farooqi, Melinda G. Pauly, Daniel S. Wechsler, Rodney R. Miles, Joel M. Reid, Cynthia D. Kihei, Lia Gore, Elizabeth A. Raetz, Stephen P. Hunger, Mignon L. Loh, Patrick A. Brown
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Infants less than 1 year old diagnosed with KMT2A-rearranged (KMT2A-r) acute lymphoblastic leukemia (ALL) are at high risk of remission failure, relapse, and death due to leukemia, despite intensive therapies. Infant KMT2A-r ALL blasts are characteri
Externí odkaz:
https://doaj.org/article/b91198f427bc4dd39ad94aff06c2ddf3
Autor:
Kaylyn Utley Lyons, Lia Gore
Publikováno v:
Haematologica, Vol 109, Iss 6 (2024)
Immunotherapy has revolutionized treatment for a wide variety of cancers yet its use has been relatively limited in childhood malignancies. With the introduction of bispecific T-cell engagers (BiTE®) and chimeric antigen T-cell receptor technologies
Externí odkaz:
https://doaj.org/article/b27b5573bebd465bad43ff267a39709e
Autor:
Erin M. Guest, John A. Kairalla, Joanne M. Hilden, ZoAnn E. Dreyer, Andrew J. Carroll, Nyla A. Heerema, Cindy Y. Wang, Meenakshi Devidas, Lia Gore, Wanda L. Salzer, Naomi J. Winick, William L. Carroll, Elizabeth A. Raetz, Michael Borowitz, Mignon L. Loh, Stephen P. Hunger, Patrick A. Brown
Publikováno v:
Haematologica, Vol 107, Iss 5 (2022)
Externí odkaz:
https://doaj.org/article/6f75c85ff88943d48d1cd90df26deea7
Autor:
Andrew DJ. Pearson, Carl Allen, Jason Fangusaro, Caroline Hutter, Olaf Witt, Susan Weiner, Gregory Reaman, Mark Russo, Pratiti Bandopadhayay, Sama Ahsan, Amy Barone, Elly Barry, Teresa de Rojas, Michael Fisher, Elizabeth Fox, Julia Glade Bender, Lia Gore, Darren Hargrave, Doug Hawkins, Brent Kreider, Abraham J. Langseth, Giovanni Lesa, Franca Ligas, Marcelo Marotti, Lynley V. Marshall, Kahina Nasri, Koen Norga, Karsten Nysom, Alberto Pappo, Gianluca Rossato, Nicole Scobie, Malcolm Smith, Elliot Stieglitz, Brenda Weigel, Amy Weinstein, Ruth Viana, Dominik Karres, Gilles Vassal
Publikováno v:
European Journal of Cancer. 177:120-142
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e51cb81f4e064a01a1e1d2c5bc7d4f56
https://doi.org/10.1016/j.ejca.2022.09.036
https://doi.org/10.1016/j.ejca.2022.09.036
Autor:
Lia Gore, Timothy J. Triche, Jason E. Farrar, Daniel Wai, Christophe Legendre, Gerald C. Gooden, Winnie S. Liang, John Carpten, David Lee, Frank Alvaro, Margaret E. Macy, Carola Arndt, Philip Barnette, Todd Cooper, Laura Martin, Aru Narendran, Jessica Pollard, Soheil Meshinchi, Jessica Boklan, Robert J. Arceci, Bodour Salhia
Publikováno v:
Clinical Epigenetics, Vol 9, Iss 1, Pp 1-13 (2017)
Abstract Background Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly, we co
Externí odkaz:
https://doaj.org/article/de503b27da154bdf96868461841e32fb
Autor:
Emily M. Hsieh, Regina M. Myers, Bonnie Yates, Colleen Annesley, Samuel John, Agne Taraseviciute, Seth M. Steinberg, Jennifer Sheppard, Perry Chung, Lee Chen, Daniel W. Lee, Amanda DiNofia, Stephan A. Grupp, Michael R. Verneris, Theodore W. Laetsch, Deepa Bhojwani, Patrick A. Brown, Michael A. Pulsipher, Susan R. Rheingold, Rebecca A. Gardner, Lia Gore, Nirali N. Shah, Adam J. Lamble
Publikováno v:
Blood Advances. 6:5222-5226
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90d68d14ce10585b90054349031f77f4
https://doi.org/10.1182/bloodadvances.2022008093
https://doi.org/10.1182/bloodadvances.2022008093
Autor:
Michael J. Burke, Wanda L. Salzer, Meenakshi Devidas, Yunfeng Dai, Lia Gore, Joanne M. Hilden, Eric Larsen, Karen R. Rabin, Patrick A. Zweidler-McKay, Michael J. Borowitz, Brent Wood, Nyla A. Heerema, Andrew J. Carroll, Naomi Winick, William L. Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger
Publikováno v:
Haematologica, Vol 104, Iss 5 (2019)
With modern chemotherapy, approximately 90% of patients with pediatric acute lymphoblastic leukemia are now cured. However, subsets of patients can be identified who remain at very high risk of relapse with expected 4-year disease-free survival rates
Externí odkaz:
https://doaj.org/article/400df5614bb0423c96a66827ab493ef8
Autor:
Lucas Moreno, Steven G. DuBois, Julia Glade Bender, Audrey Mauguen, Nick Bird, Vickie Buenger, Michela Casanova, François Doz, Elizabeth Fox, Lia Gore, Douglas S. Hawkins, Shai Izraeli, David T.W. Jones, Pamela R. Kearns, Jan J. Molenaar, Karsten Nysom, Stefan Pfister, Gregory Reaman, Malcolm Smith, Brenda Weigel, Gilles Vassal, Christian Michel Zwaan, Xavier Paoletti, Alexia Iasonos, Andrew D.J. Pearson
Publikováno v:
Scientia
PURPOSE There is an increasing need to evaluate innovative drugs for childhood cancer using combination strategies. Strong biological rationale and clinical experience suggest that multiple agents will be more efficacious than monotherapy for most di
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42cfed0b001a0a7bb4dbc82e8b4ec2a0
https://hdl.handle.net/11351/9922
https://hdl.handle.net/11351/9922
Autor:
Laura E. Hogan, Patrick A. Brown, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, Teena Bhatla, Michael J. Borowitz, Elizabeth A. Raetz, Andrew Carroll, Nyla A. Heerema, Gerhard Zugmaier, Elad Sharon, Melanie B. Bernhardt, Stephanie A. Terezakis, Lia Gore, James A. Whitlock, Stephen P. Hunger, Mignon L. Loh
Publikováno v:
Journal of Clinical Oncology.
PURPOSE Blinatumomab, a bispecific T-cell engager immunotherapy, is efficacious in relapsed/refractory B-cell ALL (B-ALL) and has a favorable toxicity profile. One aim of the Children's Oncology Group AALL1331 study was to compare survival of patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ebb4e2001e477a780b6c6b700673cad4
https://doi.org/10.1200/jco.22.02200
https://doi.org/10.1200/jco.22.02200